AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02318199 — intervention group
Intervention type: PROCEDURE
Intervention: Anesthesia recovery after intracranial surgery
Description: Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
Study NCT00607893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
Study NCT00607893 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Description: Participants will use the lower pressure CPAP every night for 8 weeks.
Study NCT03979313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897
Description: Anti-RSV monoclonal antibody with an extended half-life
Study NCT03979313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% (w/v) saline
Study NCT03977480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemay007
Description: Hemay007 will be orally administered.
Study NCT03977480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04413045 — intervention group
Intervention type: OTHER
Intervention: Prevalence of COVID-19
Description: All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
Study NCT05522478 — intervention group
Intervention type: DEVICE
Intervention: Fall risk
Description: Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.
Study NCT03437967 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LightForce EXPi
Description: LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
Study NCT04523376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
Study NCT00865605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate 0.05% Ointment, single exposure
Description: A: Other Subjects received Alpharma/Purepac USHP formulated products
Study NCT00865605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate® 0.05% ointment, single exposure
Description: Subjects received Bristol-Myers Squibb Company formulated products
Study NCT03228082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Description: Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
Study NCT03246178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MSD-HSCT
Description: 1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed.
Study NCT03246178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFD-HSCT
Description: 1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed.
Study NCT03617588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium-68 THP-PSMA
Description: Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
Study NCT02398344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
Study NCT02398344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Sham
Description: Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
Study NCT01896024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motive-oriented therapeutic relationship/Plan Analysis
Study NCT03868254 — intervention group
Intervention type: DEVICE
Intervention: XEN Group
Description: Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
Study NCT02934646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic treatment
Description: Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
Study NCT02169232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope
Study NCT02169232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic
Study NCT03868254 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
Study NCT01253642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
Study NCT01253642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01253642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01253642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenelzine Sulfate
Description: Given PO
Study NCT00867516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
Study NCT00867516 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infusion without ALD518'
Description: 250 cc Normal saline IV over one hour Weeks 1 and 8.
Study NCT02310412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTERCEPT treated platelets
Study NCT01835821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prosthetic crowns
Description: prosthetic crowns
Study NCT00967317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auris-Sedina
Description: Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor.
Study NCT00967317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otosynalar®
Description: Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
Study NCT02320006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
Study NCT02320006 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
Study NCT04130321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camu camu
Description: 3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
Study NCT04130321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of placebo daily during 12 weeks
Study NCT03306667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral single dosing
Study NCT02494960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The brief smoking cessation AWARD model
Description: * Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again.
Study NCT02494960 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
Study NCT02908126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin drug
Study NCT00938678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim Hospira
Description: Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
Study NCT00938678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (Amgen)
Description: Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
Study NCT03410628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore
Description: Non-invasive vagal nerve stimulator
Study NCT01963195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
Study NCT03753685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396(Ensartinib) Capsule
Description: All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
Study NCT03558542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiopulmonary rehabilitation plus neurorehabilitation
Description: Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
Study NCT03974386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris blood purification set
Description: Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
Study NCT05448040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: Tooth extraction and preservation with a biomaterial
Study NCT00731419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS
Description: Comparing plastic and metal stents
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol-mknl
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, IT, PO, or SC
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV, IT, PO, or SC
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01451658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study NCT01666938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
Study NCT01134536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (OS) Oral Solution
Description: Tapentadol OS Bodyweight \<20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight >=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
Study NCT04204603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-506
Description: Tablets for oral administration
Study NCT03502824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PuraPly® Antimicrobial Wound Matrix
Description: PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
Study NCT03502824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC for Pressure Ulcers
Description: SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
Study NCT02965482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wright Nebulizer
Description: Roxon Medi-Tech, Montreal, QC, Canada
Study NCT02965482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerogen Solo Nebulizer
Description: Aerogen Ltd., Galway, Ireland
Study NCT01516216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX + bevacizumab
Study NCT01516216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT03598296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large size tube
Description: Patients in Group A are inserted the large size tube (28F).
Study NCT03598296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drainage ball
Description: Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
Study NCT02650752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib in Tandem With Capecitabine
Study NCT00439439 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Beamer Ablation (Argon Plasma Coagulation)
Description: APC-Beamerablation of heterotopic gastric mucosa
Study NCT00439439 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Beamer Ablation (Argon Plasma Coagulation)
Description: APC-Beamerablation of heterotopic gastric mucosa
Study NCT02143687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate altitude sojourn
Description: Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
Study NCT02143687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate altitude sojourn
Description: Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
Study NCT02143687 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Moderate altitude sojourn
Description: Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
Study NCT02143687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low altitude sojourn
Description: Low altitude baseline evaluations will be performed during a stay at Zurich (490)
Study NCT02143687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low altitude sojourn
Description: Low altitude baseline evaluations will be performed during a stay at Zurich (490)
Study NCT02143687 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low altitude sojourn
Description: Low altitude baseline evaluations will be performed during a stay at Zurich (490)
Study NCT02143687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Study NCT02143687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Study NCT02143687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Study NCT02143687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham oxygen (room air)
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
Study NCT02143687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham oxygen (room air)
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m